Human papillomavirus (HPV) vaccines, which were introduced in many countries in the past
decade, have shown promising results in decreasing HPV infection and related diseases …

Human papillomavirus (HPV) vaccination prevents cervical, head and neck, and anogenital
cancers. However, global HPV vaccine coverage falls short of global targets and has seen …

Health economic evaluations are comparative analyses of alternative courses of action in
terms of their costs and consequences. The Consolidated Health Economic Evaluation …

The COVID-19 outbreak has highlighted our vulnerability to novel infections. Faced with this
threat and no effective treatment, in line with many other countries, the UK adopted enforced …

The age‐standardised incidence of cervical cancer in Europe varies widely by country
(between 3 and 25/100000 women‐years) in 2018. Human papillomavirus (HPV) vaccine …

Background Due to an increased risk of sexually transmitted infections (STIs), gay, bisexual
and other men who have sex with men (MSM) have been recommended to receive …

Making pharmaceutical research and regulation work for women | The BMJ Skip to main
content Intended for healthcare professionals Access provided by Google Indexer Subscribe …

Introduction Cervical cancer has been considered as one of the most common cancers in
women (15–44 years) globally, but the advent of the human papilloma virus (HPV) vaccine …

Abstract Objectives The Mathematical and Economic Modelling for Vaccination and
Immunisation Evaluation (MEMVIE) programme aimed to explore, capture and support the …

All EU countries have introduced Human papilloma virus (HPV) vaccination for adolescent
girls and many countries are expanding the strategy to include adolescent boys. There is …